<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505514</url>
  </required_header>
  <id_info>
    <org_study_id>2020121-8204</org_study_id>
    <nct_id>NCT04505514</nct_id>
  </id_info>
  <brief_title>Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage</brief_title>
  <acronym>IVIronPPH</acronym>
  <official_title>Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage: A Single-blinded, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's study is going to compare effectiveness of single dose intravenous iron in&#xD;
      combination with oral iron versus oral iron monotherapy in correcting haemoglobin deficit,&#xD;
      replenishing iron stores and improving clinical symptoms in women with post-partum anaemia&#xD;
      after postpartum hemorrhage without increasing the rate of adverse outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin concentration (g/dL)</measure>
    <time_frame>Six weeks after intervention</time_frame>
    <description>To evaluate the increase in hemoglobin level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum iron concentration</measure>
    <time_frame>Six weeks after intervention</time_frame>
    <description>To evaluate the increase in serum iron concentration (µmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum ferritin concentration</measure>
    <time_frame>six weeks after intervention</time_frame>
    <description>serum ferritin levels (µg/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General fatigue score</measure>
    <time_frame>Six weeks after intervention</time_frame>
    <description>Using the Multidimensional Fatigue Inventory (MFI) which will be answered by the participants, scores will be taken ranging from lowest 4, till the highest of 20. A higher score will indicate higher levels of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that had adverse effects to intravenous iron</measure>
    <time_frame>Up to six weeks after intervention</time_frame>
    <description>Any adverse effects experienced by the participant arising from the administration of intravenous iron isomaltoside will be documented and managed as per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion requirement</measure>
    <time_frame>Up to six weeks after intervention</time_frame>
    <description>Number of blood transfusions required after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post Partum Hemorrhage</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Intravenous Iron Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Iron Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Isomaltoside 1000</intervention_name>
    <description>single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.&#xD;
- infusion set will be covered for blinding</description>
    <arm_group_label>Intravenous Iron Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.&#xD;
- infusion set will be covered for blinding</description>
    <arm_group_label>Oral Iron Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iberet-Folic-500</intervention_name>
    <description>once a day dose, to start 5 days after the intervention</description>
    <arm_group_label>Intravenous Iron Group</arm_group_label>
    <arm_group_label>Oral Iron Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women who underwent spontaneous vaginal delivery with Post partum hemorrhage (PPH) ≥&#xD;
             500ml OR women who underwent lower segment caesarean section with PPH ≥ 1000 ml&#xD;
&#xD;
          -  post PPH haemoglobin level ≤ 10.0 g/dl measured within 48hrs after delivery and&#xD;
             stabilisation &amp; resuscitation.&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  Proficient in Malaysian language or English language&#xD;
&#xD;
          -  Willingness to consent for blood taking and attending follow-up at 2 weeks and 6 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refused consent to participate in trial&#xD;
&#xD;
          -  history of hemolytic anemia, Thalassemia , and sickle cell anemia&#xD;
&#xD;
          -  women with signs of sepsis (clinical or laboratory evidence-intrapartum fever &gt;38.5&#xD;
             degrees with abnormal vital signs, positive blood culture)&#xD;
&#xD;
          -  clinical or laboratory evidence of hepatic or renal, cardiovascular and hemolytic&#xD;
             abnormalities&#xD;
&#xD;
          -  history of active severe acid peptic disorder, esophagitis or hiatus hernia and&#xD;
             malabsorption syndrome.&#xD;
&#xD;
          -  Severe symptoms of anemia including dyspnoea at rest, angina pectoris, syncope or&#xD;
             transient ischemic attacks.&#xD;
&#xD;
          -  history of severe asthma, eczema or other atopic allergy&#xD;
&#xD;
          -  known allergy to iron&#xD;
&#xD;
          -  patients with known immune or inflammatory conditions (e.g. systemic lupus&#xD;
             erythematosus, rheumatoid arthritis).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carolyn Yim Chue Wai, MBBS</last_name>
    <phone>+603-79493133</phone>
    <email>drcarolyim@um.edu.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Petaling Jaya</city>
        <state>Wilayah Persekutuan Kuala Lumpur</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Yim Chue Wai, MBBS</last_name>
      <phone>+603-79493133</phone>
      <email>drcarolyim@um.edu.my</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Dr Carolyn Yim Chue Wai</investigator_full_name>
    <investigator_title>Consultant Anaesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron isomaltoside 1000</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

